-

SHAREHOLDER ALERT: Robbins LLP Announces it is Investigating CleanSpark, Inc. (CLSK) on Behalf of Shareholders

SAN DIEGO & WOODS CROSS, Utah--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating CleanSpark, Inc. (NASDAQ: CLSK) to determine whether certain CleanSpark officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. CleanSpark provides advanced software and controls technology solutions, including end-to-end microgrid energy modeling, energy market communications, and energy management solutions.

If you suffered a loss due to CleanSpark, Inc.'s misconduct, click here.

CleanSpark, Inc. (CLSK) May Have Misled Investors About its Related Party Transactions and its Customer and Contract Figures

On December 31, 2020, CleanSpark issued a press release touting its achievements and "a number of significant wins for the Company." As for outlook, the Company "forecast[ed] that our second and third fiscal quarters will again be our strongest" and projected it would "generate $20 million in revenue related to our current business segments and we expect the recent acquisition of ATL Data Center to contribute a minimum of $10 million in additional Bitcoin-based (BTC-USD) revenues for 2021."

On January 14, 2021, Culper Research published a report alleging that CleanSpark had "fabricated key elements of its business, including purported customers and contracts" and that it is "rife with undisclosed related party transactions." Specifically, the report alleged that the acquisition of ATL Data Centers, LLC "is another Gutless Promotion Attempt" and that the Company's acquisition of p2k Labs was "an undisclosed related party transaction that apparently fabricated its customers." On this news, the Company's share price fell $3.63, or 9%, to close at $35.71 per share on January 14, 2021. The stock now trades at just around $20.00.

CleanSpark, Inc. (CLSK) Shareholders Have Options

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against CleanSpark, Inc. settles or to receive free alerts about corporate executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...
Back to Newsroom